Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)

被引：0
|
作者：
Krueger, Klaus [1 ]
Selmi, Carlo [2 ,3 ]
Cantagrel, Alain [4 ]
Abad, Miguel A. [5 ]
Freudensprung, Ulrich [6 ]
Rezk, Mourad Farouk [6 ]
Addison, Janet [7 ]
机构：
[1] Med Ctr Rheumatol, Munich, Germany
[2] Humanitas Res Hosp, Rheumatol & Clin Immunol Unit, Rozzano, MI, Italy
[3] Univ Milan, B1OMETRA Dept, Milan, Italy
[4] CHU, Ctr Rheumatol, Toulouse, France
[5] Hosp Virgen Puerto, FEA Reumatol, Caceres, Spain
[6] Biogen Int GmbH, Zug, Switzerland
[7] Biogen Idec Inc, Maidenhead, Berks, England
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2537
引用
收藏
页数：2
相关论文
共 40 条
  • [1] BENEFIT STUDY: A PAN-EUROPEAN OBSERVATIONAL STUDY TO EVALUATE REAL-WORLD EFFECTIVENESS OF SB4 FOLLOWING TRANSITION FROM ORIGINATOR ETANERCEPT (ETN) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) OR AXIAL SPONDYLOARTHRITIS (AXSPA)
    Krueger, Klaus
    Selmi, Carlo
    Cantagrel, Alain
    Hernandez, Abad
    Freudensprung, Ulrich
    Rezk, Mourad Farouk
    Addison, Janet
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 717 - 718
  • [2] 'BENEFIT' Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story
    Selmi, Carlo
    Kruger, Klaus
    Cantagrel, Alain
    Hernandez, Abad
    Freudensprung, Ulrich
    Rezk, Mourad Farouk
    Addison, Janet
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [3] Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study
    Luciano, Nicoletta
    Fusaro, Enrico
    Ditto, Maria Chiara
    Ianniello, Aurora
    Bellis, Emanuela
    Bruni, Cosimo
    Viapiana, Ombretta
    Gremese, Elisa
    Migliore, Alberto
    Romoli, Ester
    Conforti, Ludovica
    Govoni, Marcello
    Matucci-Cerinic, Marco
    Selmi, Carlo
    RHEUMATOLOGY AND IMMUNOLOGY RESEARCH, 2022, 3 (01): : 31 - 37
  • [4] BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis
    Selmi, C.
    Krueger, K.
    Cantagrel, A.
    Abad Hernandez, M. A.
    Freudensprung, U.
    Rezk, M. Farouk
    Addison, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (02) : 365 - 371
  • [5] Effectiveness After Transition to SB4 (Brenzys, Etanercept Biosimilar) versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study
    Pope, Janet
    Hall, Stephen
    Bombardier, Claire
    Keystone, Edward C.
    Haraoui, Boulos
    Jones, Graeme
    Naik, Latha
    Wu, Wei David
    Ramey, Dena
    Infante, Ricardo
    Etzel, Carol
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [6] THE PROPER STUDY: RESULTS OF THE FIRST INTERIM ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS OR PSORIATIC ARTHRITIS
    Mueller-Ladner, U.
    Gaffney, K.
    Jadon, D.
    Freudensprung, U.
    Addison, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1450 - 1451
  • [7] The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
    Mueller-Ladner, Ulf
    Gaffney, Karl
    Jadon, Deepak
    Freudensprung, Ulrich
    Addison, Janet
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [8] THE PROPER STUDY: INTERIM ANALYSIS OF A PAN-EU REAL-WORLD STUDY OF SB5 BIOSIMILAR FOLLOWING TRANSITION FROM REFERENCE ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, OR PSORIATIC ARTHRITIS
    Mueller-Ladner, U.
    Gaffney, K.
    Jadon, D.
    Freudensprung, U.
    Addison, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1126 - 1127
  • [9] Effectiveness after Transition to SB4 (Brenzys, Etanercept Biosimilar) Versus Continuation of Etanercept (ETN) Originator (Enbrel) Among Rheumatoid Arthritis (RA) Patients in Low Disease Activity: A Prospective Multinational Multicenter Observational Study (COMPANION-B)
    Pope, Janet
    Hall, Stephen
    Bombardier, Claire
    Keystone, Edward
    Haraoui, Boulos
    Jones, Graeme
    Naik, Latha
    Etzel, Carol
    Ramey, Dena
    Infante, Ricardo
    Wu, David
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1155 - 1155
  • [10] The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
    Mueller-Ladner, Ulf
    Gaffney, Karl
    Jadon, Deepak
    Freudensprung, Ulrich
    Addison, Janet
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1689 - 1691
1234